遺伝子サイレンシングの市場規模、シェア、動向分析レポート：用途別、製品・サービス別、最終用途別、地域別、セグメント予測、2025～2030年

遺伝子サイレンシング市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の遺伝子サイレンシング市場規模は2030年までに212億9,000万米ドルに達し、2025年から2030年までのCAGRは13.8%で成長すると予測されています。

遺伝子疾患の認知度が高まり、効果的な治療法が急務となっていることから、市場は大きな成長を遂げています。ここ数年、RNA干渉（RNAi）、アンチセンスオリゴヌクレオチド（ASO）、CRISPRベースのアプローチなど、遺伝子サイレンシング技術の進歩により、これまで治療不可能であった遺伝性疾患の治療にブレークスルーがもたらされました。研究が進むにつれ、製薬会社やバイオテクノロジー企業は、ハンチントン病、筋ジストロフィー、希少がんなどの遺伝性疾患に苦しむ患者のアンメット・メディカル・ニーズに応えるため、遺伝子サイレンシング療法の開発に多くのリソースを割いています。このような革新的な標的治療薬に対する需要の高まりは、市場の重要な促進要因となっています。

COVID-19パンデミックは多くの分野で破壊的な影響を及ぼしたが、遺伝子ベースの治療の重要性を浮き彫りにし、遺伝子サイレンシング技術の開発を加速させました。パンデミックの間、研究機関と製薬企業間の資金提供や共同研究が活発化したことで、ワクチン技術が急速に開発され、遺伝子サイレンシング戦略が広範な疾患に対処できる可能性が浮き彫りになりました。さらに、パンデミックは遺伝子研究や創薬における技術革新への注目を高め、ウイルス感染、がん治療、自己免疫疾患などの分野における遺伝子サイレンシングソリューションの必要性を促しました。その結果、遺伝子サイレンシング技術は注目を集め、将来の精密医療において重要な要素に位置づけられるようになりました。

さらに、遺伝子サイレンシング関連サービスの利用可能性が高まっていることも、市場の拡大に拍車をかけています。受託研究機関（CRO）や受託製造機関（CMO）は、遺伝子サイレンシング療法を開発するバイオテクノロジー企業や製薬企業にとって不可欠なパートナーとなっています。これらのサービスプロバイダーは、臨床試験、規制コンプライアンス、スケーラブルな製造に関する専門知識を提供し、遺伝子サイレンシングに基づく医薬品の開発をより迅速かつ費用対効果の高いものにします。パンデミックは、堅牢でスケーラブルな生産システムの必要性を浮き彫りにし、遺伝子治療開発を支援するサービスへの需要をさらに押し上げました。この動向は、遺伝子サイレンシング製品のパイプラインが拡大し、企業がこうした高度な治療オプションに対する需要の増加に対応するために取り組む中で、今後も続くと予想されます。

遺伝子サイレンシング市場レポートハイライト

• 製品・サービス別では、サービスが予測期間中CAGR 14.2%で最速の成長が見込まれます。遺伝子サイレンシング技術の複雑さにより、臨床試験管理、規制ガイダンス、バイオインフォマティクス解析における専門家のサポートに対するニーズが高まっています。このようなカスタマイズされたソリューションやエンドツーエンドのサービスに対する需要の高まりが、市場の拡大に拍車をかけています。
• 用途別では、創薬・開発分野が市場を独占し、2024年に最大の売上シェアを獲得しました。ハイスループット・スクリーニング、バイオインフォマティクス・ツール、ゲノム・データベースの進歩により、標的同定・検証プロセスが強化され、世界市場の成長に拍車がかかると予想されます。
• 最終用途別では、製薬・バイオテクノロジー企業が市場を席巻し、2024年に最大の収益シェアを占めました。この市場を牽引しているのは、精密医療への注目の高まりと、幅広い遺伝性疾患、がん、希少疾患の治療に対する遺伝子ベースの治療法の可能性です。
• 北米は2024年に48.23%の最大シェアを占めました。希少疾患に対する感受性の高い人口の存在、市場浸透率の向上、技術的に進んだヘルスケアインフラがこの地域の成長を支えています。
• 主要市場プレイヤーの一例としては、Revvity, Inc.、Danaher、Agilent Technologies、GenScript、Merck KGaA、Thermo Fisher Scientific, Inc.、Illumina、Bio-Rad Laboratories、Bio-Techne、New England Biolabs, Inc.などが挙げられます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 遺伝子サイレンシング市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 遺伝子サイレンシング市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 遺伝子サイレンシング市場：製品・サービス別推定・動向分析

• 製品・サービス別セグメントダッシュボード
• 世界の遺伝子サイレンシング市場の製品とサービス別変動分析
• 世界の遺伝子サイレンシング市場規模と動向分析（製品・サービス別、2018年～2030年）
• 製品
  • RNAi
  • CRISPR-Cas9
  • アンチセンスオリゴヌクレオチド
  • その他
• サービス

第5章 遺伝子サイレンシング市場：用途別推定・動向分析

• 用途別セグメントダッシュボード
• 世界の遺伝子サイレンシング市場の用途別変動分析
• 世界の遺伝子サイレンシング市場規模と動向分析（用途別、2018年～2030年）
• 医薬品の発見と開発
  • 神経学
  • 腫瘍学
  • 感染症
  • 代謝性疾患
  • その他
• 治療薬製造
• 農業用途
• その他

第6章 遺伝子サイレンシング市場：最終用途別推定・動向分析

• 最終用途別セグメントダッシュボード
• 世界の遺伝子サイレンシング市場の最終用途別変動分析
• 世界の遺伝子サイレンシング市場規模と動向分析（最終用途別、2018年～2030年）
• 製薬・バイオテクノロジー企業
• 学術研究機関
• CROとCMO
• その他

第7章 遺伝子サイレンシング市場：地域用途推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域用途市場ダッシュボード
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 参入企業
• 企業市況分析、2024年
• 戦略マッピング
• 参入企業の概要と概要
  • Revvity, Inc.
  • Danaher
  • Agilent Technologies
  • GenScript
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Illumina
  • Bio-Rad Laboratories
  • Bio-Techne
  • New England Biolabs, Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America Gene Silencing Market, by Region, 2018 - 2030 (USD Million)
• Table 3 North America Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 4 North America Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 5 North America Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 6 U.S. Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 7 U.S. Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 8 U.S. Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 9 Canada Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 10 Canada Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 11 Canada Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 12 Mexico Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 13 Mexico Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 14 Mexico Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 15 Europe Gene Silencing Market, by Region, 2018 - 2030 (USD Million)
• Table 16 Europe Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 17 Europe Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 18 Europe Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 19 UK Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 20 UK Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 21 UK Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 22 Germany Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 23 Germany Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 24 Germany Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 25 Italy Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 26 Italy Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 27 Italy Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 28 France Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 29 France Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 30 France Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 31 Spain Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 32 Spain Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 33 Spain Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 34 Sweden Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 35 Sweden Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 36 Sweden Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 37 Denmark Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 38 Denmark Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 39 Denmark Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 40 Norway Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 41 Norway Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 42 Norway Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific Gene Silencing Market, by Region, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 47 China Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 48 China Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 49 China Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 50 Japan Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 51 Japan Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 52 Japan Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 53 India Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 54 India Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 55 India Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 56 South Korea Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 57 South Korea Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 58 South Korea Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 59 Australia Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 60 Australia Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 61 Australia Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 62 Thailand Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 63 Thailand Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 64 Thailand Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 65 Latin America Gene Silencing Market, by Region, 2018 - 2030 (USD Million)
• Table 66 Latin America Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 67 Latin America Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 68 Latin America Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 69 Brazil Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 70 Brazil Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 71 Brazil Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 72 Argentina Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 73 Argentina Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 74 Argentina Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 75 Middle East Africa Gene Silencing Market, by Region, 2018 - 2030 (USD Million)
• Table 76 Middle East Africa Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 77 Middle East Africa Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 78 Middle East Africa Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 79 South Africa Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 80 South Africa Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 81 South Africa Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 85 UAE Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 86 UAE Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 87 UAE Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)
• Table 88 Kuwait Gene Silencing Market, by Product & Service, 2018 - 2030 (USD Million)
• Table 89 Kuwait Gene Silencing Market, by Application, 2018 - 2030 (USD Million)
• Table 90 Kuwait Gene Silencing Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Data Triangulation Techniques
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value-Chain-Based Sizing & Forecasting
• Fig. 6 QFD Modeling for Market Share Assessment
• Fig. 7 Market formulation & Validation
• Fig. 8 Gene Silencing Market: Market Outlook
• Fig. 9 Parent Market Outlook
• Fig. 10 Related/Ancillary Market Outlook
• Fig. 11 Penetration and Growth Prospect Mapping
• Fig. 12 Industry Value Chain Analysis
• Fig. 13 Gene Silencing Market Driver Impact
• Fig. 14 Gene Silencing Market Restraint Impact
• Fig. 15 Gene Silencing Market Strategic Initiatives Analysis
• Fig. 16 Gene Silencing Market: Product & Service Movement Analysis
• Fig. 17 Gene Silencing Market: Product & Service Outlook and Key Takeaways
• Fig. 18 Products Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 19 RNAi Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 20 miRNA Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 21 siRNA Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 22 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 23 CRISPR-Cas9 Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 24 CRISPR Kits & Reagents Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 25 CRISPR Libraries Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 26 Others Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 27 Antisense Oligonucleotides Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 28 Others Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 29 Services Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 30 Gene Silencing Market: Application Movement Analysis
• Fig. 31 Gene Silencing Market: Application Outlook and Key Takeaways
• Fig. 32 Drug Discovery & Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Neurology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Infectious Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Metabolic Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Therapeutics Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Agricultural Applications Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Gene Silencing Market: End-Use Movement Analysis
• Fig. 42 Gene Silencing Market: End-Use Outlook and Key Takeaways
• Fig. 43 Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Academic & Research Institutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 45 CROs & CMOs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Global Gene Silencing Market: Regional Movement Analysis
• Fig. 48 Global Gene Silencing Market: Regional Outlook and Key Takeaways
• Fig. 49 North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 50 U.S. Country Dynamics
• Fig. 51 U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Canada Country Dynamics
• Fig. 53 Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Mexico Country Dynamics
• Fig. 55 Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 57 UK Country Dynamics
• Fig. 58 UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Germany Country Dynamics
• Fig. 60 Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 61 France Country Dynamics
• Fig. 62 France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Italy Country Dynamics
• Fig. 64 Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Spain Country Dynamics
• Fig. 66 Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Denmark Country Dynamics
• Fig. 68 Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Sweden Country Dynamics
• Fig. 70 Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Norway Country Dynamics
• Fig. 72 Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 74 China Country Dynamics
• Fig. 75 China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Japan Country Dynamics
• Fig. 77 Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 78 India Country Dynamics
• Fig. 79 India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Thailand Country Dynamics
• Fig. 81 Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 82 South Korea Country Dynamics
• Fig. 83 South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Australia Country Dynamics
• Fig. 85 Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Brazil Country Dynamics
• Fig. 88 Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Argentina Country Dynamics
• Fig. 90 Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Middle East and Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 92 South Africa Country Dynamics
• Fig. 93 South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Saudi Arabia Country Dynamics
• Fig. 95 Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 96 UAE Country Dynamics
• Fig. 97 UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 98 Kuwait Country Dynamics
• Fig. 99 Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 100 Market Position of Key Market Players

Gene Silencing Market Growth & Trends:

The global gene silencing market size is expected to reach USD 21.29 billion by 2030 and is expected to grow at 13.8% CAGR from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is experiencing significant growth due to increasing recognition of genetic disorders and urgent need for effective therapies. Over the past few years, advancements in gene silencing technologies, including RNA interference (RNAi), antisense oligonucleotides (ASOs), and CRISPR-based approaches, have led to breakthroughs in treating previously untreatable genetic diseases. As research intensifies, pharmaceutical and biotechnology companies are allocating more resources to developing gene silencing therapies to address the unmet medical needs of patients suffering from genetic conditions such as Huntington's disease, muscular dystrophy, and rare cancers. This growing demand for innovative, targeted therapies is a key driver for the market.

The COVID-19 pandemic, while disruptive in many areas, also highlighted the importance of gene-based therapies and accelerated the development of gene silencing technologies. During the pandemic, increased funding and collaboration between research institutions and pharmaceutical companies led to the rapid development of vaccine technologies, highlighting the potential of gene silencing strategies for tackling a wide range of diseases. In addition, the pandemic led to a greater focus on genetic research and innovation in drug discovery, driving the need for gene silencing solutions in areas such as viral infections, cancer treatment, and autoimmune disorders. As a result, gene silencing technologies have garnered more attention, positioning them as a critical component in the future of precision medicine.

Furthermore, the growing availability of gene silencing-related services has fueled market expansion. Contract research organizations (CROs) and contract manufacturing organizations (CMOs) have become integral partners for biotech and pharmaceutical companies developing gene silencing therapies. These service providers offer expertise in clinical trials, regulatory compliance, and scalable manufacturing, enabling faster and more cost-effective development of gene silencing-based drugs. The pandemic underscored the need for robust and scalable production systems, driving further demand for services that support gene therapy development. This trend is expected to continue as the pipeline for gene silencing products expands and as companies work to meet the increasing demand for these advanced therapeutic options.

Gene Silencing Market Report Highlights:

• By product & service, services is expected to witness the fastest growth with a CAGR of 14.2% during the forecast period. The complexity of gene silencing techniques has created a need for expert support in clinical trial management, regulatory guidance, and bioinformatics analysis. This rising demand for customized solutions and end-to-end services is fueling market expansion
• By application, the drug discovery & development segment dominated the market and captured the largest revenue share in 2024. Advances in high-throughput screening, bioinformatics tools, and genomic databases have enhanced target identification and validation processes and are expected to fuel global market growth
• By end use, the pharmaceutical & biotechnology companies segment dominated the market and accounted for the largest revenue share in 2024. The market is driven by the increasing focus on precision medicine and the potential of gene-based therapies to treat a wide range of genetic disorders, cancers, and rare diseases
• North America held the largest share of 48.23% in 2024. The presence of a population with high susceptibility to rare diseases, increased market penetration rates, and technologically advanced healthcare infrastructure support the region's growth
• A few of the key market players include Revvity, Inc., Danaher, Agilent Technologies, GenScript, Merck KGaA, Thermo Fisher Scientific, Inc., Illumina, Bio-Rad Laboratories, Bio-Techne, New England Biolabs, Inc.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product & Service
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Gene Silencing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Genetic Disorders
    • 3.2.1.2. Technological Advancements in Delivery Systems
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Development Costs and Complex Manufacturing
    • 3.2.2.2. Regulatory and Ethical Challenges
• 3.3. Gene Silencing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Gene Silencing Market: Product & Service Estimates & Trend Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. Global Gene Silencing Market Product & Service Movement Analysis
• 4.3. Global Gene Silencing Market Size & Trend Analysis, by Product & Service, 2018 - 2030 (USD Million)
• 4.4. Products
• 4.5. Products Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
  • 4.5.1. RNAi
    • 4.5.1.1. RNAi Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.1.2. miRNA
      • 4.5.1.2.1. miRNA Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.1.3. siRNA
      • 4.5.1.3.1. siRNA Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.1.4. Others
    • 4.5.1.5. Others Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.2. CRISPR-Cas9
    • 4.5.2.1. CRISPR-Cas9 Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2.2. CRISPR Kits & Reagents
      • 4.5.2.2.1. CRISPR Kits & Reagents Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2.3. CRISPR Libraries
      • 4.5.2.3.1. CRISPR Libraries Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2.4. Others
    • 4.5.2.5. Others Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.3. Antisense Oligonucleotides
    • 4.5.3.1. Antisense Oligonucleotides Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Others Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Services Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)

Chapter 5. Gene Silencing Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Gene Silencing Market Application Movement Analysis
• 5.3. Global Gene Silencing Market Size & Trend Analysis, by Application, 2018 - 2030 (USD Million)
• 5.4. Drug Discovery & Development
• 5.5. Drug Discovery & Development Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
  • 5.5.1. Neurology
    • 5.5.1.1. Neurology Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.2. Oncology
    • 5.5.2.1. Oncology Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.3. Infectious Diseases
    • 5.5.3.1. Infectious Diseases Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.4. Metabolic Diseases
    • 5.5.4.1. Metabolic Diseases Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.5. Others
    • 5.5.5.1. Others Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Therapeutics Manufacturing
  • 5.6.1. Therapeutics Manufacturing Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
• 5.7. Agricultural Applications
  • 5.7.1. Agricultural Applications Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)

Chapter 6. Gene Silencing Market: End Use Estimates & Trend Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Global Gene Silencing Market End Use Movement Analysis
• 6.3. Global Gene Silencing Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Pharmaceutical & Biotechnology Companies Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Academic & Research Institutes Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
• 6.6. CROs & CMOs
  • 6.6.1. CROs & CMOs Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)

Chapter 7. Gene Silencing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Strategy Mapping
• 8.4. Participants Overview
  • 8.4.1. Revvity, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Danaher
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Agilent Technologies
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. GenScript
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Merck KGaA
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Thermo Fisher Scientific, Inc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Illumina
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Bio-Rad Laboratories
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Bio-Techne
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. New England Biolabs, Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives